Generic Drug Delays Cost U.S. Payers Millions
Problems surrounding an Indian company's launch of generic versions of three blockbuster drugs have preserved millions in revenue for the brand-name makers, reports The Wall Street Journal. Meanwhile, Swiss pharmaceutical giant Novartis projects its overhaul will boost profits, and the impact of a $1,000-a-pill drug to treat hepatitis C is examined.